These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19941078)

  • 1. Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.
    Dakin H; Petrou S; Haggard M; Benge S; Williamson I
    Qual Life Res; 2010 Feb; 19(1):65-80. PubMed ID: 19941078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ventilation tube insertion on quality of life in children with persistent otitis media with effusion.
    Sanyaolu LN; Cannings-John R; Butler CC; Francis NA
    Clin Otolaryngol; 2020 Mar; 45(2):239-247. PubMed ID: 31869494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.
    Williamson I; Benge S; Barton S; Petrou S; Letley L; Fasey N; Abangma G; Dakin H; Little P
    Health Technol Assess; 2009 Aug; 13(37):1-144. PubMed ID: 19671372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial.
    Petrou S; Dakin H; Abangma G; Benge S; Williamson I
    Value Health; 2010 Aug; 13(5):543-51. PubMed ID: 20345546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial.
    Williamson I; Benge S; Barton S; Petrou S; Letley L; Fasey N; Haggard M; Little P
    BMJ; 2009 Dec; 339():b4984. PubMed ID: 20015903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision-scored parental report questions and HL-scaled tympanometry as informative measures of hearing in otitis media 1: Large-sample evidence on determinants and complementarity to pure-tone audiometry.
    Milovanovic J; Filipovic SA; Marchisio P; Haggard MP; Zhang MF; Spencer H;
    Int J Pediatr Otorhinolaryngol; 2016 Apr; 83():113-31. PubMed ID: 26968065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion.
    Bhargava R; Chakravarti A
    Am J Otolaryngol; 2014; 35(6):766-70. PubMed ID: 25151658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychometric evaluation of the OM8-30 questionnaire in Dutch children with otitis media.
    Timmerman AA; Meesters CM; Anteunis LJ; Chenault MN; Haggard MP
    Eur Arch Otorhinolaryngol; 2008 Sep; 265(9):1047-56. PubMed ID: 18288479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients.
    Rashidi AA; Anis AH; Marra CA
    Health Qual Life Outcomes; 2006 Apr; 4():25. PubMed ID: 16626489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline comparison of three health utility measures and the feeling thermometer among participants in the Action to Control Cardiovascular Risk in Diabetes trial.
    Raisch DW; Feeney P; Goff DC; Narayan KM; O'Connor PJ; Zhang P; Hire DG; Sullivan MD
    Cardiovasc Diabetol; 2012 Jul; 11():35. PubMed ID: 22515638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translation and cultural adaptation of Health Utilities Index (HUI) Mark 2 (HUI2) and Mark 3 (HUI3) with application to survivors of childhood cancer in Brazil.
    Shimoda S; de Camargo B; Horsman J; Furlong W; Lopes LF; Seber A; Barr RD
    Qual Life Res; 2005 Jun; 14(5):1407-12. PubMed ID: 16047515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.
    Neumann PJ; Sandberg EA; Araki SS; Kuntz KM; Feeny D; Weinstein MC
    Med Decis Making; 2000; 20(4):413-22. PubMed ID: 11059474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the health utilities indices Mark 2 and Mark 3 in type 2 diabetes.
    Maddigan SL; Feeny DH; Johnson JA;
    Med Decis Making; 2003; 23(6):489-501. PubMed ID: 14672109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons.
    Feeny D; Furlong W; Saigal S; Sun J
    Soc Sci Med; 2004 Feb; 58(4):799-809. PubMed ID: 14672594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutual concurrent validity of the child health questionnaire and the health utilities index: an exploratory analysis using survivors of childhood cancer.
    Nixon Speechley K; Maunsell E; Desmeules M; Schanzer D; Landgraf JM; Feeny DH; Barrera ME
    Int J Cancer Suppl; 1999; 12():95-105. PubMed ID: 10679879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States.
    Luo N; Johnson JA; Shaw JW; Coons SJ
    Med Care; 2009 Jan; 47(1):53-60. PubMed ID: 19106731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints.
    Grutters JP; Joore MA; van der Horst F; Verschuure H; Dreschler WA; Anteunis LJ
    Qual Life Res; 2007 Oct; 16(8):1439-49. PubMed ID: 17647093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping EQ-5D utility scores from the PedsQL™ generic core scales.
    Khan KA; Petrou S; Rivero-Arias O; Walters SJ; Boyle SE
    Pharmacoeconomics; 2014 Jul; 32(7):693-706. PubMed ID: 24715604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence on the construct validity of the Health Utilities Index Mark 2 and Mark 3 in patients with chronic kidney disease.
    Davison SN; Jhangri GS; Feeny DH
    Qual Life Res; 2008 Aug; 17(6):933-42. PubMed ID: 18543076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of preference-based utilities of the Short-Form 36 Health Survey and Health Utilities Index before and after treatment of patients with intermittent claudication.
    Bosch JL; Halpern EF; Gazelle GS
    Med Decis Making; 2002; 22(5):403-9. PubMed ID: 12365482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.